PreludeDx enters into preferred provider agreement with MultiPlan

Over 590 Oklahoma Auctions End Tomorrow 05/12 - Bid Now
Over 450 Total Lots Up For Auction at Two Locations - CA 05/14, NJ 05/24

PreludeDx enters into preferred provider agreement with MultiPlan

Press releases may be edited for formatting or style | March 25, 2021 Rad Oncology
LAGUNA HILLS, Calif., March 25, 2021/PRNewswire/-- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today that it has entered into an agreement with MultiPlan, Inc., the nation's leading provider of healthcare cost management solutions to participate in MultiPlan's primary (PHCS) and complementary (MultiPlan) networks. Under terms of the agreement, more than 60 million members and nearly 1 million providers will have access to DCISionRT at discounted rates. DCISionRT a DCIS radio-genomic test, is the only test to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS).

"We are excited to initiate this agreement that will significantly expand the availability of DCISionRT," said Dan Forche, President and CEO of PreludeDx. "For the first time, MultiPlan's clients, their members and network providers will have access to DCISionRT, a molecular genomic test based on an individual patient's biology that determines if surgery alone, or surgery coupled with radiation therapy is appropriate for DCIS, at contracted rates."

DCISionRT combines the latest innovations in molecular biology with artificial intelligence and machine learning to deliver the most advanced DCIS test available, enabling truly personalized treatment. In a recent multi-site study of 474 patients, DCISionRT substantially reclassified DCIS patient risk compared to traditional clinical and pathological risk assessment. For example, 53% of patients with low or intermediate grade DCIS (grade1or 2) were upstaged to elevated risk by DCISionRT and 30% of patients with high grade DCIS (grade 3) were downstaged to low risk by DCISionRT, potentially obviating the need for follow-on radiation.1

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

"As we expand our network, we remain focused on providing healthcare payors with access to the latest innovations to improve patient outcomes while managing costs," said Bruce Singleton, MultiPlan's Senior Vice President, Network Development Strategy. "We are delighted to team with PreludeDx and provide their first of its kind test for DCIS patients."


About MultiPlan
MultiPlan is committed to helping healthcare payers manage the cost of care, improve their competitiveness, and inspire positive change. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets clients' needs and customizes innovative solutions that combine its payment integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 payors in the commercial health, government, property and casualty markets, and saves these companies more than $19 billion annually.

You Must Be Logged In To Post A Comment